Leukocyte Surface Antigen CD47 Market Report

Global Leukocyte Surface Antigen CD47 Market Study Report 2022 Historical Trends, Growth, and Forecast to 2028

  • POSTDATE：Feb 26, 2022
  • PAGES：221
  • REPORT CODE：GMM779860
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • Leukocyte Surface Antigen CD47 market report explains the definition, types, applications, major countries, and major players of the Leukocyte Surface Antigen CD47 market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.

    The report contains qualitative and quantitative analysis of the entire industry.

    The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.

    By Player:

    • Trillium Therapeutics Inc

    • Forty Seven Inc

    • Aurigene Discovery Technologies Ltd

    • Celgene Corp

    • Surface Oncology Inc

    By Type:

    • B-6H12

    • ALX-148

    • CC-90002

    • PSTx-23

    • Others

    By End-User:

    • Lymphoma

    • Ovarian Cancer

    • Ischemia Reperfusion Injury

    • Kindney Transplant Rejection

    • Others

    By Region:

    North America

    • United States

    • Canada

    • Mexico

    Europe

    • Germany

    • UK

    • Spain

    • France

    • Italy

    • Denmark

    • Finland

    • Norway

    • Sweden

    • Poland

    • Russia

    • Turkey

    Asia-Pacific

    • China

    • Japan

    • India

    • South Korea

    • Pakistan

    • Bangladesh

    • Indonesia

    • Thailand

    • Singapore

    • Malaysia

    • Philippines

    • Vietnam

    • Others

    South America

    • Brazil

    • Colombia

    • Chile

    • Argentina

    • Venezuela

    • Peru

    • Puerto Rico

    • Ecuador

    • Others

    GCC

    • Bahrain

    • Kuwait

    • Oman

    • Qatar

    • Saudi Arabia

    • United Arab Emirates

    Africa

    • Nigeria

    • South Africa

    • Egypt

    • Algeriat

    • Others

    Oceania

    • Australia

    • New Zealand

  • TABLE OF CONTENT

    1. Global Leukocyte Surface Antigen CD47 Executive Summary

    • 1.1 Introduction

    • 1.2 Market Panorama, 2022

    2 Coronavirus Impact

    • 2.1 Leukocyte Surface Antigen CD47 Outlook to 2028- Original Forecasts

    • 2.2 Leukocyte Surface Antigen CD47 Outlook to 2028- COVID-19 Affected Forecasts

    • 2.3 Impact on Industry

    3 Strategic Analytics to Boost Productivity and Profitability

    • 3.1 Potential Market Drivers and Opportunities

    • 3.2 New Challenges and Strategies

    • 3.3 Short Term and Long Term Leukocyte Surface Antigen CD47 Market Trends

    4 Key Inferences

    5 Market Overview

    • 5.1 Current Market Scenario

    • 5.2 Porter's Five Forces Analysis

      • 5.2.1 Bargaining Power of Suppliers

      • 5.2.2 Bargaining Power of Consumers

      • 5.2.3 Threat of New Entrants

      • 5.2.4 Threat of Substitute Product and Services

      • 5.2.5 Competitive Rivalry within the Industry

    6 Global Leukocyte Surface Antigen CD47 Market- Recent Developments

    • 6.1 Leukocyte Surface Antigen CD47 Market News and Developments

    • 6.2 Leukocyte Surface Antigen CD47 Market Deals Landscape

    7 Leukocyte Surface Antigen CD47 Raw Materials and Cost Structure Analysis

    • 7.1 Leukocyte Surface Antigen CD47 Key Raw Materials

    • 7.2 Leukocyte Surface Antigen CD47 Price Trend of Key Raw Materials

    • 7.3 Leukocyte Surface Antigen CD47 Key Suppliers of Raw Materials

    • 7.4 Leukocyte Surface Antigen CD47 Market Concentration Rate of Raw Materials

    • 7.5 Leukocyte Surface Antigen CD47 Cost Structure Analysis

      • 7.5.1 Leukocyte Surface Antigen CD47 Raw Materials Analysis

      • 7.5.2 Leukocyte Surface Antigen CD47 Labor Cost Analysis

      • 7.5.3 Leukocyte Surface Antigen CD47 Manufacturing Expenses Analysis

    8 Global Leukocyte Surface Antigen CD47 Import and Export Analysis (Top 10 Countries)

    • 8.1 Global Leukocyte Surface Antigen CD47 Import by Region (Top 10 Countries) (2017-2028)

    • 8.2 Global Leukocyte Surface Antigen CD47 Export by Region (Top 10 Countries) (2017-2028)

    9 Global Leukocyte Surface Antigen CD47 Market Outlook by Types and Applications to 2022

    • 9.1 Global Leukocyte Surface Antigen CD47 Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global B-6H12 Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global ALX-148 Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global CC-90002 Consumption and Growth Rate (2017-2022)

      • 9.1.4 Global PSTx-23 Consumption and Growth Rate (2017-2022)

      • 9.1.5 Global Others Consumption and Growth Rate (2017-2022)

    • 9.2 Global Leukocyte Surface Antigen CD47 Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Lymphoma Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Ovarian Cancer Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Ischemia Reperfusion Injury Consumption and Growth Rate (2017-2022)

      • 9.2.4 Global Kindney Transplant Rejection Consumption and Growth Rate (2017-2022)

      • 9.2.5 Global Others Consumption and Growth Rate (2017-2022)

    10 Region and Country-wise Leukocyte Surface Antigen CD47 Market Analysis and Outlook till 2022

    • 10.1 Global Leukocyte Surface Antigen CD47 Consumption (2017-2022)

    • 10.2 North America Consumption Analysis

      • 10.2.1 United States Leukocyte Surface Antigen CD47 Consumption (2017-2022)

      • 10.2.2 Canada Leukocyte Surface Antigen CD47 Consumption (2017-2022)

      • 10.2.3 Mexico Leukocyte Surface Antigen CD47 Consumption (2017-2022)

    • 10.3 Europe Consumption Analysis

      • 10.3.1 Germany Leukocyte Surface Antigen CD47 Consumption (2017-2022)

      • 10.3.2 UK Leukocyte Surface Antigen CD47 Consumption (2017-2022)

      • 10.3.3 Spain Leukocyte Surface Antigen CD47 Consumption (2017-2022)

      • 10.3.4 Belgium Leukocyte Surface Antigen CD47 Consumption (2017-2022)

      • 10.3.5 France Leukocyte Surface Antigen CD47 Consumption (2017-2022)

      • 10.3.6 Italy Leukocyte Surface Antigen CD47 Consumption (2017-2022)

      • 10.3.7 Denmark Leukocyte Surface Antigen CD47 Consumption (2017-2022)

      • 10.3.8 Finland Leukocyte Surface Antigen CD47 Consumption (2017-2022)

      • 10.3.9 Norway Leukocyte Surface Antigen CD47 Consumption (2017-2022)

      • 10.3.10 Sweden Leukocyte Surface Antigen CD47 Consumption (2017-2022)

      • 10.3.11 Poland Leukocyte Surface Antigen CD47 Consumption (2017-2022)

      • 10.3.12 Russia Leukocyte Surface Antigen CD47 Consumption (2017-2022)

      • 10.3.13 Turkey Leukocyte Surface Antigen CD47 Consumption (2017-2022)

    • 10.4 APAC Consumption Analysis

      • 10.4.1 China Leukocyte Surface Antigen CD47 Consumption (2017-2022)

      • 10.4.2 Japan Leukocyte Surface Antigen CD47 Consumption (2017-2022)

      • 10.4.3 India Leukocyte Surface Antigen CD47 Consumption (2017-2022)

      • 10.4.4 South Korea Leukocyte Surface Antigen CD47 Consumption (2017-2022)

      • 10.4.5 Pakistan Leukocyte Surface Antigen CD47 Consumption (2017-2022)

      • 10.4.6 Bangladesh Leukocyte Surface Antigen CD47 Consumption (2017-2022)

      • 10.4.7 Indonesia Leukocyte Surface Antigen CD47 Consumption (2017-2022)

      • 10.4.8 Thailand Leukocyte Surface Antigen CD47 Consumption (2017-2022)

      • 10.4.9 Singapore Leukocyte Surface Antigen CD47 Consumption (2017-2022)

      • 10.4.10 Malaysia Leukocyte Surface Antigen CD47 Consumption (2017-2022)

      • 10.4.11 Philippines Leukocyte Surface Antigen CD47 Consumption (2017-2022)

      • 10.4.12 Vietnam Leukocyte Surface Antigen CD47 Consumption (2017-2022)

    • 10.5 South America Consumption Analysis

      • 10.5.1 Brazil Leukocyte Surface Antigen CD47 Consumption (2017-2022)

      • 10.5.2 Colombia Leukocyte Surface Antigen CD47 Consumption (2017-2022)

      • 10.5.3 Chile Leukocyte Surface Antigen CD47 Consumption (2017-2022)

      • 10.5.4 Argentina Leukocyte Surface Antigen CD47 Consumption (2017-2022)

      • 10.5.5 Venezuela Leukocyte Surface Antigen CD47 Consumption (2017-2022)

      • 10.5.6 Peru Leukocyte Surface Antigen CD47 Consumption (2017-2022)

      • 10.5.7 Puerto Rico Leukocyte Surface Antigen CD47 Consumption (2017-2022)

      • 10.5.8 Ecuador Leukocyte Surface Antigen CD47 Consumption (2017-2022)

    • 10.6 GCC Consumption Analysis

      • 10.6.1 Bahrain Leukocyte Surface Antigen CD47 Consumption (2017-2022)

      • 10.6.2 Kuwait Leukocyte Surface Antigen CD47 Consumption (2017-2022)

      • 10.6.3 Oman Leukocyte Surface Antigen CD47 Consumption (2017-2022)

      • 10.6.4 Qatar Leukocyte Surface Antigen CD47 Consumption (2017-2022)

      • 10.6.5 Saudi Arabia Leukocyte Surface Antigen CD47 Consumption (2017-2022)

      • 10.6.6 United Arab Emirates Leukocyte Surface Antigen CD47 Consumption (2017-2022)

    • 10.7 Africa Consumption Analysis

      • 10.7.1 Nigeria Leukocyte Surface Antigen CD47 Consumption (2017-2022)

      • 10.7.2 South Africa Leukocyte Surface Antigen CD47 Consumption (2017-2022)

      • 10.7.3 Egypt Leukocyte Surface Antigen CD47 Consumption (2017-2022)

      • 10.7.4 Algeria Leukocyte Surface Antigen CD47 Consumption (2017-2022)

    • 10.8 Oceania Consumption Analysis

      • 10.8.1 Australia Leukocyte Surface Antigen CD47 Consumption (2017-2022)

      • 10.8.2 New Zealand Leukocyte Surface Antigen CD47 Consumption (2017-2022)

    11 Global Leukocyte Surface Antigen CD47 Competitive Analysis

    • 11.1 Trillium Therapeutics Inc

      • 11.1.1 Trillium Therapeutics Inc Company Details

      • 11.1.2 Trillium Therapeutics Inc Leukocyte Surface Antigen CD47 Sales, Price, Value and Gross Profit (2017-2022)

      • 11.1.3 Trillium Therapeutics Inc Leukocyte Surface Antigen CD47 Main Business and Markets Served

      • 11.1.4 Trillium Therapeutics Inc Leukocyte Surface Antigen CD47 Product Portfolio

      • 11.1.5 Recent Research and Development Strategies

    • 11.2 Forty Seven Inc

      • 11.2.1 Forty Seven Inc Company Details

      • 11.2.2 Forty Seven Inc Leukocyte Surface Antigen CD47 Sales, Price, Value and Gross Profit (2017-2022)

      • 11.2.3 Forty Seven Inc Leukocyte Surface Antigen CD47 Main Business and Markets Served

      • 11.2.4 Forty Seven Inc Leukocyte Surface Antigen CD47 Product Portfolio

      • 11.2.5 Recent Research and Development Strategies

    • 11.3 Aurigene Discovery Technologies Ltd

      • 11.3.1 Aurigene Discovery Technologies Ltd Company Details

      • 11.3.2 Aurigene Discovery Technologies Ltd Leukocyte Surface Antigen CD47 Sales, Price, Value and Gross Profit (2017-2022)

      • 11.3.3 Aurigene Discovery Technologies Ltd Leukocyte Surface Antigen CD47 Main Business and Markets Served

      • 11.3.4 Aurigene Discovery Technologies Ltd Leukocyte Surface Antigen CD47 Product Portfolio

      • 11.3.5 Recent Research and Development Strategies

    • 11.4 Celgene Corp

      • 11.4.1 Celgene Corp Company Details

      • 11.4.2 Celgene Corp Leukocyte Surface Antigen CD47 Sales, Price, Value and Gross Profit (2017-2022)

      • 11.4.3 Celgene Corp Leukocyte Surface Antigen CD47 Main Business and Markets Served

      • 11.4.4 Celgene Corp Leukocyte Surface Antigen CD47 Product Portfolio

      • 11.4.5 Recent Research and Development Strategies

    • 11.5 Surface Oncology Inc

      • 11.5.1 Surface Oncology Inc Company Details

      • 11.5.2 Surface Oncology Inc Leukocyte Surface Antigen CD47 Sales, Price, Value and Gross Profit (2017-2022)

      • 11.5.3 Surface Oncology Inc Leukocyte Surface Antigen CD47 Main Business and Markets Served

      • 11.5.4 Surface Oncology Inc Leukocyte Surface Antigen CD47 Product Portfolio

      • 11.5.5 Recent Research and Development Strategies

    12 Global Leukocyte Surface Antigen CD47 Market Outlook by Types and Applications to 2028

    • 12.1 Global Leukocyte Surface Antigen CD47 Consumption Forecast and Growth Rate by Type (2022-2028)

      • 12.1.1 Global B-6H12 Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.2 Global ALX-148 Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.3 Global CC-90002 Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.4 Global PSTx-23 Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.5 Global Others Consumption Forecast and Growth Rate (2022-2028)

    • 12.2 Global Leukocyte Surface Antigen CD47 Consumption Forecast and Growth Rate by Application (2022-2028)

      • 12.2.1 Global Lymphoma Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.2 Global Ovarian Cancer Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.3 Global Ischemia Reperfusion Injury Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.4 Global Kindney Transplant Rejection Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.5 Global Others Consumption Forecast and Growth Rate (2022-2028)

    13 Country-wise Leukocyte Surface Antigen CD47 Market Analysis and Outlook to 2028

    • 13.1 Global Leukocyte Surface Antigen CD47 Consumption Forecast (2022-2028)

    • 13.2 North America Consumption Analysis

      • 13.2.1 United States Leukocyte Surface Antigen CD47 Consumption Forecast (2022-2028)

      • 13.2.2 Canada Leukocyte Surface Antigen CD47 Consumption Forecast (2022-2028)

      • 13.2.3 Mexico Leukocyte Surface Antigen CD47 Consumption Forecast (2022-2028)

    • 13.3 Europe Consumption Analysis

      • 13.3.1 Germany Leukocyte Surface Antigen CD47 Consumption Forecast (2022-2028)

      • 13.3.2 UK Leukocyte Surface Antigen CD47 Consumption Forecast (2022-2028)

      • 13.3.3 Spain Leukocyte Surface Antigen CD47 Consumption Forecast (2022-2028)

      • 13.3.4 Belgium Leukocyte Surface Antigen CD47 Consumption Forecast (2022-2028)

      • 13.3.5 France Leukocyte Surface Antigen CD47 Consumption Forecast (2022-2028)

      • 13.3.6 Italy Leukocyte Surface Antigen CD47 Consumption Forecast (2022-2028)

      • 13.3.7 Denmark Leukocyte Surface Antigen CD47 Consumption Forecast (2022-2028)

      • 13.3.8 Finland Leukocyte Surface Antigen CD47 Consumption Forecast (2022-2028)

      • 13.3.9 Norway Leukocyte Surface Antigen CD47 Consumption Forecast (2022-2028)

      • 13.3.10 Sweden Leukocyte Surface Antigen CD47 Consumption Forecast (2022-2028)

      • 13.3.11 Poland Leukocyte Surface Antigen CD47 Consumption Forecast (2022-2028)

      • 13.3.12 Russia Leukocyte Surface Antigen CD47 Consumption Forecast (2022-2028)

      • 13.3.13 Turkey Leukocyte Surface Antigen CD47 Consumption Forecast (2022-2028)

    • 13.4 APAC Consumption Analysis

      • 13.4.1 China Leukocyte Surface Antigen CD47 Consumption Forecast (2022-2028)

      • 13.4.2 Japan Leukocyte Surface Antigen CD47 Consumption Forecast (2022-2028)

      • 13.4.3 India Leukocyte Surface Antigen CD47 Consumption Forecast (2022-2028)

      • 13.4.4 South Korea Leukocyte Surface Antigen CD47 Consumption Forecast (2022-2028)

      • 13.4.5 Pakistan Leukocyte Surface Antigen CD47 Consumption Forecast (2022-2028)

      • 13.4.6 Bangladesh Leukocyte Surface Antigen CD47 Consumption Forecast (2022-2028)

      • 13.4.7 Indonesia Leukocyte Surface Antigen CD47 Consumption Forecast (2022-2028)

      • 13.4.8 Thailand Leukocyte Surface Antigen CD47 Consumption Forecast (2022-2028)

      • 13.4.9 Singapore Leukocyte Surface Antigen CD47 Consumption Forecast (2022-2028)

      • 13.4.10 Malaysia Leukocyte Surface Antigen CD47 Consumption Forecast (2022-2028)

      • 13.4.11 Philippines Leukocyte Surface Antigen CD47 Consumption Forecast (2022-2028)

      • 13.4.12 Vietnam Leukocyte Surface Antigen CD47 Consumption Forecast (2022-2028)

    • 13.5 South America Consumption Analysis

      • 13.5.1 Brazil Leukocyte Surface Antigen CD47 Consumption Forecast (2022-2028)

      • 13.5.2 Colombia Leukocyte Surface Antigen CD47 Consumption Forecast (2022-2028)

      • 13.5.3 Chile Leukocyte Surface Antigen CD47 Consumption Forecast (2022-2028)

      • 13.5.4 Argentina Leukocyte Surface Antigen CD47 Consumption Forecast (2022-2028)

      • 13.5.5 Venezuela Leukocyte Surface Antigen CD47 Consumption Forecast (2022-2028)

      • 13.5.6 Peru Leukocyte Surface Antigen CD47 Consumption Forecast (2022-2028)

      • 13.5.7 Puerto Rico Leukocyte Surface Antigen CD47 Consumption Forecast (2022-2028)

      • 13.5.8 Ecuador Leukocyte Surface Antigen CD47 Consumption Forecast (2022-2028)

    • 13.6 GCC Consumption Analysis

      • 13.6.1 Bahrain Leukocyte Surface Antigen CD47 Consumption Forecast (2022-2028)

      • 13.6.2 Kuwait Leukocyte Surface Antigen CD47 Consumption Forecast (2022-2028)

      • 13.6.3 Oman Leukocyte Surface Antigen CD47 Consumption Forecast (2022-2028)

      • 13.6.4 Qatar Leukocyte Surface Antigen CD47 Consumption Forecast (2022-2028)

      • 13.6.5 Saudi Arabia Leukocyte Surface Antigen CD47 Consumption Forecast (2022-2028)

      • 13.6.6 United Arab Emirates Leukocyte Surface Antigen CD47 Consumption Forecast (2022-2028)

    • 13.7 Africa Consumption Analysis

      • 13.7.1 Nigeria Leukocyte Surface Antigen CD47 Consumption Forecast (2022-2028)

      • 13.7.2 South Africa Leukocyte Surface Antigen CD47 Consumption Forecast (2022-2028)

      • 13.7.3 Egypt Leukocyte Surface Antigen CD47 Consumption Forecast (2022-2028)

      • 13.7.4 Algeria Leukocyte Surface Antigen CD47 Consumption Forecast (2022-2028)

    • 13.8 Oceania Consumption Analysis

      • 13.8.1 Australia Leukocyte Surface Antigen CD47 Consumption Forecast (2022-2028)

      • 13.8.2 New Zealand Leukocyte Surface Antigen CD47 Consumption Forecast (2022-2028)

    14 Conclusions


    The List of Tables and Figures

    • Table Definition of Leukocyte Surface Antigen CD47

    • Figure of Leukocyte Surface Antigen CD47 Picture

    • Table Global Leukocyte Surface Antigen CD47 Import by Region (Top 10 Countries) (2017-2028)

    • Table Global Leukocyte Surface Antigen CD47 Export by Region (Top 10 Countries) (2017-2028)

    • Figure Global B-6H12 Consumption and Growth Rate (2017-2022)

    • Figure Global ALX-148 Consumption and Growth Rate (2017-2022)

    • Figure Global CC-90002 Consumption and Growth Rate (2017-2022)

    • Figure Global PSTx-23 Consumption and Growth Rate (2017-2022)

    • Figure Global Others Consumption and Growth Rate (2017-2022)

    • Figure Global Lymphoma Consumption and Growth Rate (2017-2022)

    • Figure Global Ovarian Cancer Consumption and Growth Rate (2017-2022)

    • Figure Global Ischemia Reperfusion Injury Consumption and Growth Rate (2017-2022)

    • Figure Global Kindney Transplant Rejection Consumption and Growth Rate (2017-2022)

    • Figure Global Others Consumption and Growth Rate (2017-2022)

    • Figure Global Leukocyte Surface Antigen CD47 Consumption by Country (2017-2022)

    • Table North America Leukocyte Surface Antigen CD47 Consumption by Country (2017-2022)

    • Figure United States Leukocyte Surface Antigen CD47 Consumption and Growth Rate (2017-2022)

    • Figure Canada Leukocyte Surface Antigen CD47 Consumption and Growth Rate (2017-2022)

    • Figure Mexico Leukocyte Surface Antigen CD47 Consumption and Growth Rate (2017-2022)

    • Table Europe Leukocyte Surface Antigen CD47 Consumption by Country (2017-2022)

    • Figure Germany Leukocyte Surface Antigen CD47 Consumption and Growth Rate (2017-2022)

    • Figure UK Leukocyte Surface Antigen CD47 Consumption and Growth Rate (2017-2022)

    • Figure Spain Leukocyte Surface Antigen CD47 Consumption and Growth Rate (2017-2022)

    • Figure Belgium Leukocyte Surface Antigen CD47 Consumption and Growth Rate (2017-2022)

    • Figure France Leukocyte Surface Antigen CD47 Consumption and Growth Rate (2017-2022)

    • Figure Italy Leukocyte Surface Antigen CD47 Consumption and Growth Rate (2017-2022)

    • Figure Denmark Leukocyte Surface Antigen CD47 Consumption and Growth Rate (2017-2022)

    • Figure Finland Leukocyte Surface Antigen CD47 Consumption and Growth Rate (2017-2022)

    • Figure Norway Leukocyte Surface Antigen CD47 Consumption and Growth Rate (2017-2022)

    • Figure Sweden Leukocyte Surface Antigen CD47 Consumption and Growth Rate (2017-2022)

    • Figure Poland Leukocyte Surface Antigen CD47 Consumption and Growth Rate (2017-2022)

    • Figure Russia Leukocyte Surface Antigen CD47 Consumption and Growth Rate (2017-2022)

    • Figure Turkey Leukocyte Surface Antigen CD47 Consumption and Growth Rate (2017-2022)

    • Table APAC Leukocyte Surface Antigen CD47 Consumption by Country (2017-2022)

    • Figure China Leukocyte Surface Antigen CD47 Consumption and Growth Rate (2017-2022)

    • Figure Japan Leukocyte Surface Antigen CD47 Consumption and Growth Rate (2017-2022)

    • Figure India Leukocyte Surface Antigen CD47 Consumption and Growth Rate (2017-2022)

    • Figure South Korea Leukocyte Surface Antigen CD47 Consumption and Growth Rate (2017-2022)

    • Figure Pakistan Leukocyte Surface Antigen CD47 Consumption and Growth Rate (2017-2022)

    • Figure Bangladesh Leukocyte Surface Antigen CD47 Consumption and Growth Rate (2017-2022)

    • Figure Indonesia Leukocyte Surface Antigen CD47 Consumption and Growth Rate (2017-2022)

    • Figure Thailand Leukocyte Surface Antigen CD47 Consumption and Growth Rate (2017-2022)

    • Figure Singapore Leukocyte Surface Antigen CD47 Consumption and Growth Rate (2017-2022)

    • Figure Malaysia Leukocyte Surface Antigen CD47 Consumption and Growth Rate (2017-2022)

    • Figure Philippines Leukocyte Surface Antigen CD47 Consumption and Growth Rate (2017-2022)

    • Figure Vietnam Leukocyte Surface Antigen CD47 Consumption and Growth Rate (2017-2022)

    • Table South America Leukocyte Surface Antigen CD47 Consumption by Country (2017-2022)

    • Figure Brazil Leukocyte Surface Antigen CD47 Consumption and Growth Rate (2017-2022)

    • Figure Colombia Leukocyte Surface Antigen CD47 Consumption and Growth Rate (2017-2022)

    • Figure Chile Leukocyte Surface Antigen CD47 Consumption and Growth Rate (2017-2022)

    • Figure Argentina Leukocyte Surface Antigen CD47 Consumption and Growth Rate (2017-2022)

    • Figure Venezuela Leukocyte Surface Antigen CD47 Consumption and Growth Rate (2017-2022)

    • Figure Peru Leukocyte Surface Antigen CD47 Consumption and Growth Rate (2017-2022)

    • Figure Puerto Rico Leukocyte Surface Antigen CD47 Consumption and Growth Rate (2017-2022)

    • Figure Ecuador Leukocyte Surface Antigen CD47 Consumption and Growth Rate (2017-2022)

    • Table GCC Leukocyte Surface Antigen CD47 Consumption by Country (2017-2022)

    • Figure Bahrain Leukocyte Surface Antigen CD47 Consumption and Growth Rate (2017-2022)

    • Figure Kuwait Leukocyte Surface Antigen CD47 Consumption and Growth Rate (2017-2022)

    • Figure Oman Leukocyte Surface Antigen CD47 Consumption and Growth Rate (2017-2022)

    • Figure Qatar Leukocyte Surface Antigen CD47 Consumption and Growth Rate (2017-2022)

    • Figure Saudi Arabia Leukocyte Surface Antigen CD47 Consumption and Growth Rate (2017-2022)

    • Figure United Arab Emirates Leukocyte Surface Antigen CD47 Consumption and Growth Rate (2017-2022)

    • Table Africa Leukocyte Surface Antigen CD47 Consumption by Country (2017-2022)

    • Figure Nigeria Leukocyte Surface Antigen CD47 Consumption and Growth Rate (2017-2022)

    • Figure South Africa Leukocyte Surface Antigen CD47 Consumption and Growth Rate (2017-2022)

    • Figure Egypt Leukocyte Surface Antigen CD47 Consumption and Growth Rate (2017-2022)

    • Figure Algeria Leukocyte Surface Antigen CD47 Consumption and Growth Rate (2017-2022)

    • Table Oceania Leukocyte Surface Antigen CD47 Consumption by Country (2017-2022)

    • Figure Australia Leukocyte Surface Antigen CD47 Consumption and Growth Rate (2017-2022)

    • Figure New Zealand Leukocyte Surface Antigen CD47 Consumption and Growth Rate (2017-2022)

    • Table Trillium Therapeutics Inc Company Details

    • Table Trillium Therapeutics Inc Leukocyte Surface Antigen CD47 Sales, Price, Value and Gross Profit (2017-2022)

    • Table Trillium Therapeutics Inc Leukocyte Surface Antigen CD47 Main Business and Markets Served

    • Table Trillium Therapeutics Inc Leukocyte Surface Antigen CD47 Product Portfolio

    • Table Forty Seven Inc Company Details

    • Table Forty Seven Inc Leukocyte Surface Antigen CD47 Sales, Price, Value and Gross Profit (2017-2022)

    • Table Forty Seven Inc Leukocyte Surface Antigen CD47 Main Business and Markets Served

    • Table Forty Seven Inc Leukocyte Surface Antigen CD47 Product Portfolio

    • Table Aurigene Discovery Technologies Ltd Company Details

    • Table Aurigene Discovery Technologies Ltd Leukocyte Surface Antigen CD47 Sales, Price, Value and Gross Profit (2017-2022)

    • Table Aurigene Discovery Technologies Ltd Leukocyte Surface Antigen CD47 Main Business and Markets Served

    • Table Aurigene Discovery Technologies Ltd Leukocyte Surface Antigen CD47 Product Portfolio

    • Table Celgene Corp Company Details

    • Table Celgene Corp Leukocyte Surface Antigen CD47 Sales, Price, Value and Gross Profit (2017-2022)

    • Table Celgene Corp Leukocyte Surface Antigen CD47 Main Business and Markets Served

    • Table Celgene Corp Leukocyte Surface Antigen CD47 Product Portfolio

    • Table Surface Oncology Inc Company Details

    • Table Surface Oncology Inc Leukocyte Surface Antigen CD47 Sales, Price, Value and Gross Profit (2017-2022)

    • Table Surface Oncology Inc Leukocyte Surface Antigen CD47 Main Business and Markets Served

    • Table Surface Oncology Inc Leukocyte Surface Antigen CD47 Product Portfolio

    • Figure Global B-6H12 Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global ALX-148 Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global CC-90002 Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global PSTx-23 Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Others Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Lymphoma Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Ovarian Cancer Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Ischemia Reperfusion Injury Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Kindney Transplant Rejection Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Others Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Leukocyte Surface Antigen CD47 Consumption Forecast by Country (2022-2028)

    • Table North America Leukocyte Surface Antigen CD47 Consumption Forecast by Country (2022-2028)

    • Figure United States Leukocyte Surface Antigen CD47 Consumption Forecast and Growth Rate (2022-2028)

    • Figure Canada Leukocyte Surface Antigen CD47 Consumption Forecast and Growth Rate (2022-2028)

    • Figure Mexico Leukocyte Surface Antigen CD47 Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Leukocyte Surface Antigen CD47 Consumption Forecast by Country (2022-2028)

    • Figure Germany Leukocyte Surface Antigen CD47 Consumption Forecast and Growth Rate (2022-2028)

    • Figure UK Leukocyte Surface Antigen CD47 Consumption Forecast and Growth Rate (2022-2028)

    • Figure Spain Leukocyte Surface Antigen CD47 Consumption Forecast and Growth Rate (2022-2028)

    • Figure Belgium Leukocyte Surface Antigen CD47 Consumption Forecast and Growth Rate (2022-2028)

    • Figure France Leukocyte Surface Antigen CD47 Consumption Forecast and Growth Rate (2022-2028)

    • Figure Italy Leukocyte Surface Antigen CD47 Consumption Forecast and Growth Rate (2022-2028)

    • Figure Denmark Leukocyte Surface Antigen CD47 Consumption Forecast and Growth Rate (2022-2028)

    • Figure Finland Leukocyte Surface Antigen CD47 Consumption Forecast and Growth Rate (2022-2028)

    • Figure Norway Leukocyte Surface Antigen CD47 Consumption Forecast and Growth Rate (2022-2028)

    • Figure Sweden Leukocyte Surface Antigen CD47 Consumption Forecast and Growth Rate (2022-2028)

    • Figure Poland Leukocyte Surface Antigen CD47 Consumption Forecast and Growth Rate (2022-2028)

    • Figure Russia Leukocyte Surface Antigen CD47 Consumption Forecast and Growth Rate (2022-2028)

    • Figure Turkey Leukocyte Surface Antigen CD47 Consumption Forecast and Growth Rate (2022-2028)

    • Table APAC Leukocyte Surface Antigen CD47 Consumption Forecast by Country (2022-2028)

    • Figure China Leukocyte Surface Antigen CD47 Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Leukocyte Surface Antigen CD47 Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Leukocyte Surface Antigen CD47 Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Leukocyte Surface Antigen CD47 Consumption Forecast and Growth Rate (2022-2028)

    • Figure Pakistan Leukocyte Surface Antigen CD47 Consumption Forecast and Growth Rate (2022-2028)

    • Figure Bangladesh Leukocyte Surface Antigen CD47 Consumption Forecast and Growth Rate (2022-2028)

    • Figure Indonesia Leukocyte Surface Antigen CD47 Consumption Forecast and Growth Rate (2022-2028)

    • Figure Thailand Leukocyte Surface Antigen CD47 Consumption Forecast and Growth Rate (2022-2028)

    • Figure Singapore Leukocyte Surface Antigen CD47 Consumption Forecast and Growth Rate (2022-2028)

    • Figure Malaysia Leukocyte Surface Antigen CD47 Consumption Forecast and Growth Rate (2022-2028)

    • Figure Philippines Leukocyte Surface Antigen CD47 Consumption Forecast and Growth Rate (2022-2028)

    • Figure Vietnam Leukocyte Surface Antigen CD47 Consumption Forecast and Growth Rate (2022-2028)

    • Table South America Leukocyte Surface Antigen CD47 Consumption Forecast by Country (2022-2028)

    • Figure Brazil Leukocyte Surface Antigen CD47 Consumption Forecast and Growth Rate (2022-2028)

    • Figure Colombia Leukocyte Surface Antigen CD47 Consumption Forecast and Growth Rate (2022-2028)

    • Figure Chile Leukocyte Surface Antigen CD47 Consumption Forecast and Growth Rate (2022-2028)

    • Figure Argentina Leukocyte Surface Antigen CD47 Consumption Forecast and Growth Rate (2022-2028)

    • Figure Venezuela Leukocyte Surface Antigen CD47 Consumption Forecast and Growth Rate (2022-2028)

    • Figure Peru Leukocyte Surface Antigen CD47 Consumption Forecast and Growth Rate (2022-2028)

    • Figure Puerto Rico Leukocyte Surface Antigen CD47 Consumption Forecast and Growth Rate (2022-2028)

    • Figure Ecuador Leukocyte Surface Antigen CD47 Consumption Forecast and Growth Rate (2022-2028)

    • Table GCC Leukocyte Surface Antigen CD47 Consumption Forecast by Country (2022-2028)

    • Figure Bahrain Leukocyte Surface Antigen CD47 Consumption Forecast and Growth Rate (2022-2028)

    • Figure Kuwait Leukocyte Surface Antigen CD47 Consumption Forecast and Growth Rate (2022-2028)

    • Figure Oman Leukocyte Surface Antigen CD47 Consumption Forecast and Growth Rate (2022-2028)

    • Figure Qatar Leukocyte Surface Antigen CD47 Consumption Forecast and Growth Rate (2022-2028)

    • Figure Saudi Arabia Leukocyte Surface Antigen CD47 Consumption Forecast and Growth Rate (2022-2028)

    • Figure United Arab Emirates Leukocyte Surface Antigen CD47 Consumption Forecast and Growth Rate (2022-2028)

    • Table Africa Leukocyte Surface Antigen CD47 Consumption Forecast by Country (2022-2028)

    • Figure Nigeria Leukocyte Surface Antigen CD47 Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Africa Leukocyte Surface Antigen CD47 Consumption Forecast and Growth Rate (2022-2028)

    • Figure Egypt Leukocyte Surface Antigen CD47 Consumption Forecast and Growth Rate (2022-2028)

    • Figure Algeria Leukocyte Surface Antigen CD47 Consumption Forecast and Growth Rate (2022-2028)

    • Table Oceania Leukocyte Surface Antigen CD47 Consumption Forecast by Country (2022-2028)

    • Figure Australia Leukocyte Surface Antigen CD47 Consumption Forecast and Growth Rate (2022-2028)

    • Figure New Zealand Leukocyte Surface Antigen CD47 Consumption Forecast and Growth Rate (2022-2028)

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US